FDA Approves a Pill Combination for Breast Cancer That Kept Growing on Hormone Therapy

On Nov. 16, 2026, the U.S. Food and Drug Administration approved giredestrant, an oral estrogen receptor blocker that Genentech will sell as Wilserdly, for use with everolimus in adults whose advanced breast cancer carries a mutation in the ESR1 gene. The agency also authorized a test, FoundationOne Liquid CDx, to identify those patients by reading tumor DNA that circulates in the blood.
The combination is cleared for breast cancer that grows in response to estrogen and is not driven by the HER2 protein, once the disease has spread or advanced locally. The FDA's indication covers patients whose cancer came back during or after hormone-based treatment given after surgery, and patients whose cancer kept growing on at least one hormone-based regimen after it had spread.
The approval notification rests on evERA Breast Cancer, an open-label trial that randomly assigned 373 adults, 207 of whom had tumors carrying the mutation. In that group, the agency reports a median of 10 months before the disease worsened among patients taking giredestrant with everolimus, against 5.5 months among those given a hormone drug of the doctor's choosing. The choices were exemestane, fulvestrant or tamoxifen, each taken with everolimus. Tumors shrank in roughly twice as many patients on giredestrant. Survival data were immature when that analysis was done, the agency adds, so the trial does not show whether patients live longer.
The FDA lists mouth inflammation, rash, fatigue, diarrhea, muscle and joint pain, lung inflammation and nausea as the side effects seen in at least a fifth of patients on the combination. The prescribing information carries warnings for a slow heartbeat and for harm to a fetus.
The review ran under Project Orbis, a program through which regulators in several countries examine a cancer drug at the same time. The FDA worked on it with Health Canada and Israel's Ministry of Health, and says the applications may still be under review at those agencies. Full prescribing information for Wilserdly will be posted on Drugs@FDA.
Sources
Medical Disclaimer: This content is provided for general informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition, concern, symptom, or treatment decision.
